Genentech Reports Results of Polivy (polatuzumab vedotin) in P-III (POLARIX) Study for the Treatment of Diffuse Large B-Cell Lymphoma
Shots:
- The P-III (POLARIX) study evaluates the efficacy, safety, and PK of Polivy + R-CHP vs R-CHOP in a ratio (1:1) in 879 patients with previously untreated DLBCL
- The results showed an improvement in PFS after a median follow-up of 28.2mos, 27% reduction in the risk of disease progression, relapse, or death, safety outcomes were consistent with those seen in previous trials & the safety profile was comparable for Polivy + R-CHP vs R-CHOP. The results were presented at ASH 2021 & published in the NEJM
- Polivy is used as an off-the-shelf, fixed-duration treatment option in the R/R DLBCL setting and is approved in combination with bendamustine and Rituxan in 70+ countries globally, including EU and the US
Ref: Businesswire | Image: Genentech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com